About Gennova
Gennova is a Healthcare company based in Pune (India) founded in 2006. Biotherapeutics for life-threatening diseases are developed, produced, and commercialized. The company has 705 employees. Its chief executive, as recorded, is Sanjay Singh. Its Indian entity Gennova Biopharmaceuticals Limited reported revenue of ₹376 Cr. Gennova offers products and services including Elaxim®, GEMCOVAC®-OM, Hamsyl®, TENECTASE®, and Xgrast®. Its focus areas include Life Sciences, Nephrology, Drugs and Oncology.
Company details
Founded in 2006 in Pune, India, biotherapeutics targeting cardiovascular, neurology, nephrology, and oncology indications are developed and commercialized. Recombinant products are manufactured using bacterial, yeast, and mammalian expression platforms, with expertise applied in perfusion-based continuous manufacturing. Biosimilars, vaccines, generics, and innovative products have been commercialized, including an mRNA-based platform for vaccine development.
- Headquarters Pune, India
- Employees 705
- SectorsHealthcare
- Website gennova.bio
- Social LinkedIn
- Legal Name Gennova Biopharmaceuticals Limited
- Date of Incorporation 19 Jun, 2001
- Jurisdiction Pune, Maharashtra, India
- Annual Revenue₹376 Cr
FY 2023 · +10% YoY
- Net Profit₹30.71 Cr
FY 2023 · 8% margin
- EBITDA₹95.68 Cr
FY 2023 · 25% margin
- InvestorsEuropean Union
& 1 more
- Employee Count705
Associated legal entities of Gennova
Gennova is associated with 2 registered companies on The Company Check; the primary company is Gennova Biopharmaceuticals Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Gennova Biopharmaceuticals Limited CIN U24231PN2001PLC016253 | Active | 19 Jun 2001 | Pune, Maharashtra | ₹376 Cr | 705 | 8 | View details |
| Emcure Pharmaceuticals Limited Listed CIN L24231PN1981PLC024251 | Active | 16 Apr 1981 | Pune, Maharashtra | ₹9,335 Cr | 6,877 | 13 | View details |
Products & Services of Gennova
Gennova offers a comprehensive portfolio of products and services, including Elaxim®, GEMCOVAC®-OM, Hamsyl®, TENECTASE®, and Xgrast®.
Biotherapeutic for cardiac care and acute myocardial infarction treatment.
mRNA-based vaccine targeting emerging diseases and health threats.
Treatment for renal care and anemia-related complications in patients.
Clot buster for stroke care to minimize treatment time and disabilities.
Solution for cancer care to address neutropenia and enhance treatments.
Funding Insights of Gennova
- Total Rounds 2
- Investors Count 2
All 2 funding rounds of Gennova with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | Seed | – | – | ||
| Apr 2020 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Gennova
Gennova has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Department of Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Biotechnology research, guidelines, and funding by the Government of India. | 1986 | dbtindia.gov.in | Delhi, India |
Investor details for Gennova
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Gennova Biopharmaceuticals Limited (Gennova)
Gennova Biopharmaceuticals Limited is the primary company behind Gennova. The boards of the 2 registered companies of Gennova currently have 13 directors; the longest-serving is Satish Ramanlal Mehta, appointed in 1981. 45 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Satish Ramanlal Mehta DIN 00118691 | Managing Director | 16 Apr 1981 | 45 yrs 6 mo | Emcure Pharmaceuticals Limited |
| Mukund Keshao Gurjar DIN 00026843 | Whole-time director | 23 Jul 2001 | 25 yrs 3 mo | Emcure Pharmaceuticals Limited |
| Sunil Rajanikant Mehta DIN 00118469 | Whole-time director | 05 Jun 2013 | 13 yrs 5 mo | Emcure Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited |
| Namita Vikas Thapar DIN 05318899 | Whole-time director | 28 Jul 2014 | 12 yrs 3 mo | Emcure Pharmaceuticals Limited |
| Sanjay Singh DIN 01693705 | CEO | 27 Oct 2020 | 6 yrs | Gennova Biopharmaceuticals Limited |
| Shailesh Kripalu Ayyangar DIN 00268076 | Director | 16 Apr 2021 | 5 yrs 6 mo | Emcure Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited |
| Vijay Keshav Gokhale DIN 09134089 | Director | 16 Apr 2021 | 5 yrs 6 mo | Emcure Pharmaceuticals Limited |
| Vidya Rajiv Yeravdekar DIN 02183179 | Director | 16 Apr 2021 | 5 yrs 6 mo | Emcure Pharmaceuticals Limited |
| Samit Satish Mehta DIN 00332562 | Whole-time director | 28 Jul 2022 | 4 yrs 3 mo | Emcure Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited |
| Kavita Singh DIN 06784250 | Director | 24 Jan 2023 | 3 yrs 9 mo | Gennova Biopharmaceuticals Limited |
| Vikas Madan Thapar DIN 02617012 | Additional Director | 07 Nov 2024 | 2 yrs | Gennova Biopharmaceuticals Limited |
| Chinnadharavaram Sundaresan Muralidharan DIN 00014740 | Director | 01 Apr 2026 | 7 mo | Emcure Pharmaceuticals Limited |
| Raman Pillai Raghu Kumar DIN 01983106 | Director | 06 Aug 2026 | 3 mo | Emcure Pharmaceuticals Limited |
People of Gennova
1 people are tracked at Gennova (1 in leadership); the tracked headcount is 705.
| Name | Role | Group |
|---|---|---|
| CEO & Director | Leadership |
Complete people profiles for Gennova
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Gennova
Figures of Gennova Biopharmaceuticals Limited, the primary company behind Gennova, for FY 2023. Revenue was ₹376 Cr (+10% year on year). Net profit was ₹30.71 Cr (8% margin). EBITDA was ₹95.68 Cr (25% margin). Revenue has grown at a compounded annual rate of +21% over three years and +17% over five years.
- ₹376 CrRevenue · FY 2023 · +10% YoY
- ₹30.71 CrNet profit · 8% margin
- ₹95.68 CrEBITDA · 25% margin
- ₹5.51 CrPaid-up capital
- 705Employees (provident fund records)
- +21%Revenue CAGR, 3 years
- +17%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Gennova Biopharmaceuticals Limited are on its company page.
Detailed financial statements for Gennova
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Gennova
3 dated milestones of Gennova across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Gennova is founded.
- Funding First funding round.
- Funding Latest funding round, Seed,.
Web traffic of Gennova
The website of Gennova (gennova.bio) receives about 5.9K visits a month.
- Monthly visits5.9K
▲ 29.1% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gennova
Complete news archive for Gennova
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gennova
Gennova was founded in 2006 and raised its 1st funding round 14 years after it was founded.
Gennova is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Sanjay Singh is the CEO of Gennova, as recorded in our data.
Gennova has 705 employees.
The primary company behind Gennova, Gennova Biopharmaceuticals Limited, reported revenue of â‚ą376 Cr for FY 2023, up 10% year on year.
Founded in 2006 in Pune, India, biotherapeutics targeting cardiovascular, neurology, nephrology, and oncology indications are developed and commercialized. Recombinant products are manufactured using bacterial, yeast, and mammalian expression platforms, with expertise applied in perfusion-based continuous manufacturing. Biosimilars, vaccines, generics, and innovative products have been commercialized, including an mRNA-based platform for vaccine development.
Gennova offers Elaxim®, GEMCOVAC®-OM, Hamsyl®, TENECTASE®, and Xgrast®.
Gennova has 2 investors. Key investors include European Union, and Department of Biotechnology.
Gennova is associated with 2 legal entities: Gennova Biopharmaceuticals Limited, Emcure Pharmaceuticals Limited.
The legal entities of Gennova currently have 16 directors, including Shailesh Kripalu Ayyangar, Satish Ramanlal Mehta, Mukund Keshao Gurjar and others.